Anti-Cancer drug NSC-631570 (Ukrain): Induction of the apoptosis in cancer cells
International Conference on Pathology and Surgical Pathology
September 06-07, 2018 | Edinburgh, Scotland
Wassil Nowicky
Ukrainian Anti-Cancer Institute, Austria
Scientific Tracks Abstracts : J Pathol Dis Biol
Abstract:
In the study on the erythroleucemia cells KâÂÂ562, it was revealed NSCâÂÂ631570 to bring about the bimodal death of cancer cells. At lower concentrations of NSCâÂÂ631570, cancer cells die in as a consequence of apoptosis. At higher concentrations, the formation of microtubules is inhibited and polyploidy occurs. In the tests on human cervix carcinoma cells HeLa, squamous carcinoma cells WHCO5, normal kidney cell line Graham 293, and transformed kidney cell line Vero from African green monkey the researchers of the University of Pretoria, South Africa revealed NSCâÂÂ631570 âÂÂis selectively toxic to malignant cells by causing a metaphase block which is characterised by abnormal chromosomal distribution, and results in the formation of micronuclei and in apoptosis. The scientists of the Eberhard Karl University (TuÃÂbingen, Germany) investigated the effect of NSCâÂÂ631570 on the cell survival, the cell cycle modification and the apoptosis induction alone and combined with radiation (IR). They discovered NSCâÂÂ631570 combined with IR increased the toxicity against the cell lines CCLâÂÂ221 and UâÂÂ138MG. The normal human skin and lung fibroblasts were protected from the damaging effects of IR. Estimating the cell proliferation according to the BrdU uptake in the cell lines AsPC1, BxPC3, MiaPaCa2, Jurkat, and THPâÂÂ1 and the cell cycle phases by means of Giemsa staining, the authors established NSCâÂÂ631570 at a dose of 10 üg/ml brought about a considerable accumulation of cancer cells in the G2/M phase after 24 h incubation. The apoptosis rate in the peripheral mononuclears was similar at the same incubation conditions. Moreover, the mitogene stimulated lymphocytes showed increased blastogen reaction. Effect of NSCâÂÂ631570 on cell survival and apoptosis in the androgenâÂÂindependent prostate cancer cell line PCâÂÂ3 was studied. Cell viability was assessed using the dimethyl thiazolyl tetrazolium bromide (MTT) method in PCâÂÂ3 cells after treatment with Ukrain. The IC50 value was observed in 10 üg concentration of Ukrain. Bax, Bad, and FasL mRNA expression was analyzed by reverse transcriptaseâÂÂpolymerase chain reaction, and protein expressions of pâÂÂAkt, BclâÂÂ2, and caspase 10 were determined by westernâÂÂblot analysis. Nuclei were stained with 4âÂÂ,6âÂÂdiamidinoâÂÂ2â phenylindole, dihydrochloride (DAPI). NSCâÂÂ631570 significantly increased the proâÂÂapoptotic mRNA expression of Bad, Bax, and FasL; decreased the cell survival protein pâÂÂAkt and the antiâÂÂapoptotic protein BclâÂÂ2; and increased the protein levels of cleaved poly(ADP)âÂÂribose polymerase (PARP) and caspaseâÂÂ10. The results of this study suggest that NSCâÂÂ631570 decreases the cell survival of androgenâÂÂindependent prostate cancer cells.
Biography:
Wassil Nowicky, Director of “Nowicky Pharma” and President of the Ukrainian Anti- Cancer Institute (Vienna, Austria). Has finished his study at the Radiotechnical faculty of the technical University of Lviv (Ukraine) with the end of 1955 with graduation to “Diplomingeniueur” in 1960 which title was nostrificated in Austria in 1975. Inventor of the anticancer preparation on basis of celandine alkaloids “NSC-631570”. Author of over 300 scientific articles dedicated to cancer research. Dr. Wassil Nowicky is a real member of the New York Academy of Sciences, member of the European Union for Applied Immunology and of the American Association for scientific progress, honorary doctor of the Janka Kupala University in Hrodno, doctor “honoris causa” of the Open international university on complex medicine in Colombo, honorary member of the Austrian Society of a name od Albert Schweizer. He has received the award for merits of National guild of pharmacists of America. the award of Austrian Society of sanitary, hygiene and public health services and others.
E-mail: dr.nowicky@yahoo.de
PDF HTML